Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share (the "Shares")
-
Shares outstanding
-
28,743,490
-
Total 13F shares
-
18,399,795
-
Share change
-
+349,418
-
Total reported value
-
$1,136,590,687
-
Put/Call ratio
-
86%
-
Price per share
-
$61.78
-
Number of holders
-
164
-
Value change
-
+$22,032,008
-
Number of buys
-
80
-
Number of sells
-
84
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (the "Shares") (ENTA) as of Q4 2019
As of 31 Dec 2019,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (the "Shares") (ENTA) was held by
164 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,399,795 shares.
The largest 10 holders included
BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, DIMENSIONAL FUND ADVISORS LP, JANUS HENDERSON GROUP PLC, FIRST MANHATTAN CO, and Krensavage Asset Management, LLC.
This page lists
166
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.